Adverse effects of antiretroviral therapy: focus on orofacial effects.

Abstract:

:The optimum anti-HIV drug has yet to be found. This paper will summarise some of the oral adverse effects associated with antiretroviral agents against HIV. The development of antiretroviral drugs for the treatment of HIV infection has been aimed at the inactivation of two HIV enzymes: reverse transcriptase and proteases. Erythema multiforme, ulcers and xerostomia are the main oral side effects associated with reverse transcriptase inhibitors. Parotid lipomatosis, taste disturbance, xerostomia and perioral paraesthesia are oral adverse effects, which are mainly related to protease inhibitor therapy. The search for new antiretrovirals with different active mechanisms and patterns of resistance constitutes a key question in HIV treatment. The use of new drugs and drug combinations will lead to the appearance of oral lesions, which will be difficult to identify and treat and which cannot be ignored by the practitioner.

journal_name

Expert Opin Drug Saf

authors

Diz Dios P,Scully C

doi

10.1517/14740338.1.4.307

keywords:

subject

Has Abstract

pub_date

2002-11-01 00:00:00

pages

307-17

issue

4

eissn

1474-0338

issn

1744-764X

journal_volume

1

pub_type

杂志文章,评审
  • Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.

    abstract:INTRODUCTION:Trabectedin gained the approval by the European Medicines Agency (EMA) in 2007 for the treatment of patients affected by soft-tissue sarcomas (STS). Its safety and activity profiles have been assessed in many clinical trials as well as in standard clinical practice for > 10 years. AREAS COVERED:This artic...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.829037

    authors: Martin-Liberal J,Judson I

    更新日期:2013-11-01 00:00:00

  • Basiliximab: efficacy and safety evaluation in kidney transplantation.

    abstract:INTRODUCTION:Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 receptor (IL-2R). When administered intravenously at a dosage of 20 mg at the time of transplantation and 4 days later, basiliximab saturates the alpha chain of IL-2R for 4 weeks. AREAS COVERED:This review eval...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14740338.2014.861816

    authors: Ponticelli C

    更新日期:2014-03-01 00:00:00

  • Safety and immunogenicity of pneumococcal conjugate vaccines in preterm infants.

    abstract:INTRODUCTION:The introduction of pneumococcal conjugate vaccines (PCVs) in the routine immunization program has resulted in a significant decline in invasive pneumococcal diseases (IPD) around the world. Preterm infants are a special group at a high risk of invasive infection by encapsulated bacteria. However, their sl...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1597849

    authors: López-Sanguos C,Rivero Calle I,Rodriguez Tenreiro C,Raguindin PF,Martinón-Torres F

    更新日期:2019-04-01 00:00:00

  • Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.

    abstract:INTRODUCTION:Development of new drugs in oncology may have implications for cardiovascular risk. This report describes some aspects of our growing knowledge in the area of evaluating benefit-risk and may be of direct importance to scientists working in drug discovery and development. AREAS COVERED:This report of webin...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.797407

    authors: Braddock M,Heilbraun J,Mendzelevski B

    更新日期:2013-09-01 00:00:00

  • Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society.

    abstract::This meeting was convened to encourage the incorporation of empirical and mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) modelling into safety pharmacology to improve the predictability of nonclinical investigations for human outcomes. These technologies make use of mathematical expressions relating measured ...

    journal_title:Expert opinion on drug safety

    pub_type:

    doi:10.1517/14740338.6.4.465

    authors: Cavero I

    更新日期:2007-07-01 00:00:00

  • The pharmacology of bipolar disorder during pregnancy and breastfeeding.

    abstract::Treating bipolar disorder in women during reproduction presents a significant challenge to the physician. The pharmaceutical agents most commonly used for treating bipolar disorder have been associated with adverse effects when used during pregnancy and breastfeeding. Of particular concern has been the association of ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/eods.3.3.221.31074

    authors: Dodd S,Berk M

    更新日期:2004-05-01 00:00:00

  • The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance.

    abstract::Background: The safety and effectiveness of vonoprazan-based Helicobacter pylori (H. pylori) eradication therapy in routine clinical practice, and patient characteristics that influence safety and effectiveness, have not been well investigated.Methods: H. pylori-positive patients with gastric ulcer, duodenal ulcer, id...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2019.1676722

    authors: Ashida K,Honda Y,Sanada K,Takemura Y,Sakamoto S

    更新日期:2019-12-01 00:00:00

  • Examining the safety of amiodarone.

    abstract:INTRODUCTION:Amiodarone is the most widely used antiarrhythmic agent, with demonstrated effectiveness against all the spectrum of cardiac tachyarrhythmias. The risk of adverse effects acts as a limiting factor to its utilization especially in the long term. This article systematically reviews the published evidence on ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2012.660915

    authors: Santangeli P,Di Biase L,Burkhardt JD,Bai R,Mohanty P,Pump A,Natale A

    更新日期:2012-03-01 00:00:00

  • The risk of cardiovascular complications with current obesity drugs.

    abstract:INTRODUCTION:Obesity is associated with an increased risk of cardiovascular morbidity and mortality. Four medications are approved by the US Food and Drug Administration (FDA) for chronic weight management when used as an adjunct to a reduced-calorie diet and increased physical activity in adults. These medications res...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1806234

    authors: Chao AM,Wadden TA,Berkowitz RI,Quigley K,Silvestry F

    更新日期:2020-09-01 00:00:00

  • Database size and power to detect safety signals in pharmacovigilance.

    abstract::Most regulatory agencies and pharmaceutical companies focus the majority of their pharmacovigilance on safety signal identification in large databases. GlaxoSmithKline (GSK) has > 100 drugs marketed worldwide. In order to determine which database has the highest statistical power to detect safety signals in three larg...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.6.6.713

    authors: Hammond IW,Gibbs TG,Seifert HA,Rich DS

    更新日期:2007-11-01 00:00:00

  • Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.

    abstract::Background: This study aimed to measure the association of various H1-antihistamines (H1A) with Torsade de Pointes (TdP), and present a comprehensive overview of H1A-induced TdP cases reported to the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: All H1A-induced TdP cases (n = 406) were ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2021.1846717

    authors: Ali Z,Ismail M,Khan F,Sajid H

    更新日期:2021-01-01 00:00:00

  • The safety of lanreotide for neuroendocrine tumor.

    abstract:INTRODUCTION:Lanreotide autogel is a synthetic somatostatin analogue which has been FDA and EMA approved for unresectable, well to moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor. Its action is mediated by its affinity to somatostatin receptors, especially sst2 and ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1559294

    authors: Godara A,Siddiqui NS,Byrne MM,Saif MW

    更新日期:2019-01-01 00:00:00

  • Antineoplastic drug-induced bradyarrhythmias.

    abstract:INTRODUCTION:Cardiac injury is one of the most impairing side effects of anticancer treatment. The extension of the range of available drugs, the use of combination regimens and the association with radiation therapy have improved life expectancy; however, they have also caused a rising typology of cardiac toxicities, ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2012.705826

    authors: Minoia C,Giannoccaro M,Iacobazzi A,Santini D,Silvestris N,Fioretti A,Oliva S,Guarini A

    更新日期:2012-09-01 00:00:00

  • Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

    abstract:BACKGROUND:This meta-analysis has been conducted to determine the risk of elevated transaminases associated with immune checkpoint inhibitors use in patients with cancer. METHODS:Studies eligible for our analysis included randomized Phase II and III trials of patients with cancer on ipilimumab, nivolumab, pembrolizuma...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,meta分析,评审

    doi:10.1517/14740338.2015.1085969

    authors: Abdel-Rahman O,ElHalawani H,Fouad M

    更新日期:2015-10-01 00:00:00

  • Information technology for detecting medication errors and adverse drug events.

    abstract::It is estimated that over three-quarters of a million people are injured or die in hospitals each year from adverse drug events (ADEs). The majority of medical errors result from poorly designed healthcare systems rather than from negligence on the part of healthcare providers. In general, healthcare systems rely on v...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.3.5.449

    authors: Anderson JG

    更新日期:2004-09-01 00:00:00

  • Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.

    abstract::A water soluble derivative of camptothecin, irinotecan (CPT-11) is effective against small-cell lung cancer (SCLC), as well as non-SCLC and gastrointestinal cancers. This extended review of recently concluded and ongoing studies focuses on irinotecan in the treatment of limited (LD) and extensive (ED) SCLC specificall...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.5.2.303

    authors: Kawahara M

    更新日期:2006-03-01 00:00:00

  • Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients.

    abstract:INTRODUCTION:ACE-inhibitors (ACEI) and diuretics are the typical first-line antihypertensive drugs with complementary mechanisms of action. The present paper is summarizing the evidence supporting the efficacy of their combination in a broad range of hypertensive patients. AREAS COVERED:This source of data is differen...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1836151

    authors: Borghi C,Soldati M,Bragagni A,Cicero AFG

    更新日期:2020-12-01 00:00:00

  • A safety evaluation of evolocumab.

    abstract:INTRODUCTION:Evolocumab is an injectable, fully human monoclonal antibody and a member of the newest class of low density lipoprotein cholesterol (LDL-C) lowering agents called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The PCSK9 inhibitors are the most significant advance in lipid therapy since ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1389892

    authors: Roth EM

    更新日期:2018-01-01 00:00:00

  • Statin use and the risk of kidney cancer: a population-based case-control study.

    abstract:OBJECTIVE:To investigate whether the use of statins was associated with kidney cancer risk. METHODS:We conducted a population-based case-control study in Taiwan. Cases consisted of all patients who were aged 50 years and older, and had a first-time diagnosis of kidney cancer for the period between 2005 and 2009. The c...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2012.678831

    authors: Chiu HF,Kuo CC,Kuo HW,Lee IM,Lee CT,Yang CY

    更新日期:2012-07-01 00:00:00

  • Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures.

    abstract:BACKGROUND:Ximelagatran, the first oral agent in the new class of direct thrombin inhibitors, was withdrawn from the market due to increased rates of liver enzyme elevations in long-term treatments. Despite intensive pre clinical investigations the cellular mechanisms behind the observed hepatic effects remain unknown....

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.7.4.351

    authors: Ainscow EK,Pilling JE,Brown NM,Orme AT,Sullivan M,Hargreaves AC,Cooke EL,Sullivan E,Carlsson S,Andersson TB

    更新日期:2008-07-01 00:00:00

  • Typical toxic components in traditional Chinese medicine.

    abstract:INTRODUCTION:Traditional Chinese medicine (TCM) is widely used around the world. However, with its wide use has been the identification of a number of toxicological issues that have severely restricted its use in clinical treatment. The identification of these toxic substances within TCM has become somewhat of a hot to...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2012.726610

    authors: Lv W,Piao JH,Jiang JG

    更新日期:2012-11-01 00:00:00

  • Monitoring self-medication.

    abstract::Self-medication, using non-prescription drugs, is beneficial to patients, healthcare professionals, the pharmaceutical industry and governments. Although many non-prescription medications are effective, misuse and abuse of these products can arise. Monitoring of specific populations and products, in addition to data r...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740338.2.1.1

    authors: Hughes CM

    更新日期:2003-01-01 00:00:00

  • A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy.

    abstract:INTRODUCTION:The polycystic ovary syndrome (PCOS) is a very prevalent disorder in premenopausal women. Cardiovascular risk factors cluster in these patients, raising concern about the safety of the drugs commonly used to ameliorate symptoms of androgen excess in in this population at risk of cardiovascular morbidity. ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1839409

    authors: Luque-Ramírez M,Ortiz-Flores AE,Nattero-Chávez L,Escobar-Morreale HF

    更新日期:2020-12-01 00:00:00

  • Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.

    abstract:INTRODUCTION:Fingolimod (Gilenya®, FTY720) is an oral sphingosine-1-phosphate analogue that was approved by the FDA in 2010 for the treatment of relapsing forms of multiple sclerosis (MS). Fingolimod's mechanism of action is primarily related to lymphocyte sequestration in primary and secondary lymphoid tissues. Phase ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2014.920820

    authors: Ward MD,Jones DE,Goldman MD

    更新日期:2014-07-01 00:00:00

  • Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.

    abstract::Objectives: Bullous pemphigoid, an autoimmune dermatological disease, may be associated with the use of a relatively new anti-cancer drug class, PD-1 inhibitors, which includes pembrolizumab and nivolumab. This paper analyzes the signals between PD-1 inhibitors and bullous pemphigoid based upon the reported real-world...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2019.1619693

    authors: Aggarwal P

    更新日期:2019-07-01 00:00:00

  • The safety of available and emerging options for emergency contraception.

    abstract:INTRODUCTION:Emergency contraception (EC) is a way to significantly reduce the chance of becoming pregnant after an episode of unprotected intercourse. Considerable data support the safety of all available and emerging options for EC. Areas covered: This review presents a comprehensive summary of the literature regardi...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1354985

    authors: Lee JK,Schwarz EB

    更新日期:2017-10-01 00:00:00

  • E-detailing: information technology applied to pharmaceutical detailing.

    abstract:BACKGROUND:E-detailing can be best described as the use of information technology in the field of pharmaceutical detailing. It is becoming highly popular among pharmaceutical companies because it maximizes the time of the sales force, cuts down the cost of detailing and increases physician prescribing. Thus, the applic...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740330802456903

    authors: Montoya ID

    更新日期:2008-11-01 00:00:00

  • A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.

    abstract::Worldwide, women comprise > 50% of all people living with HIV and the vast majority of these women are of childbearing age. In fact, a significant proportion of these women are identified as HIV-infected during pregnancy. Preventing perinatal transmission has been one of the greatest prevention successes of the HIV ep...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740330903241584

    authors: Nurutdinova D,Overton ET

    更新日期:2009-11-01 00:00:00

  • The effect of anticholinergic agents on gastro-oesophageal reflux and related disorders.

    abstract::The most important risk factor of oesophageal adenocarcinoma is gastro-oesophageal reflux disease. Gastro-oesophageal reflux disease is in itself a common disorder, giving bothersome symptoms. In daily clinical practice, anticholinergic drugs are believed to increase the risk of gastro-oesophageal reflux through effec...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.7.2.173

    authors: van Soest EM,Dieleman JP,Kuipers EJ

    更新日期:2008-03-01 00:00:00

  • The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.

    abstract::Introduction: Clozapine remains the most effective antipsychotic for treatment-refractory schizophrenia. However, ~40% of the patients respond insufficiently to clozapine. Clozapine's effects, both beneficial and adverse, have been proposed to be partially attributable to its main metabolite, N-desmethylclozapine (NDM...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2020.1698545

    authors: Costa-Dookhan KA,Agarwal SM,Chintoh A,Tran VN,Stogios N,Ebdrup BH,Sockalingam S,Rajji TK,Remington GJ,Siskind D,Hahn MK

    更新日期:2020-01-01 00:00:00